If Celite 512 is incubated with normal plasma, an activity can then be eluted from it which corresponds to the activation of contact clotting factors XII and XI. The phenomenon was described by Waaler (1959) who called the eluate 'activation product'. The material has been in routine use in this laboratory for a number of years in the one-stage assay of factor VIII (Essien and Ingram, 1967; Hills, Ingram, and Matchett, 1970) ; it is also used in a screening test for defects of the 'contact' factors. The preparation of the reagent was described by Wilson, Ingram, and Hills (1971) , but the technique has required further study because some batches have clotted during preparation, and excessive thrombin activity has sometimes remained in the final product. Different methods of defibrinating the starting plasma have therefore been investigated, and the effect of a final adsorption with alumina has been examined.
Materials STARTING MATERIAL
Human citrated plasma taken into plastic equipment, stored at -20°C until required. Most samples were obtained from therapeutic venesections in polycythaemia. Plasma Three aliquots of the preparations of contact product made without defibrination and after ancroddefibrination were taken: one sample from each product was adsorbed with alumina gel, another pair of samples received aprotinin to 5 u/ml, and the third pair served as a control. Volumes of 0 1 ml of each sample were mixed with 0-3 ml vols of a fibrinogen solution 0 5 g/l, and incubated at 37°C. Both control samples and both those containing aprotinin had clotted after 1 hr; the adsorbed sample made without defibrination had clotted after 2 hr; but the adsorbed sample from the ancrod-treated plasma remained unclotted after 6 hr.
FIBRINOLYTIC ACTIVITY
Aliquots of 01 ml of the six samples tested in the preceding section were mixed with 0 3 ml of the fibrinogen solution 0-5 g/l and clotted with thrombin. 2 Test for fibrinolytic activity by mixing a 0-1 ml aliquot with 0 3 ml of fibrinogen solution 0 5 g/l and clot with thrombin, and observe the clot for Technical methods 5-6 hr at 37°C for dissolution; no change in the clot should be apparent over this period. 3 Test the 'contact' activity as follows. Obtain a sample of fresh, non-contacted normal citrated plasma and perform the partial thromboplastin time after 10 min preincubation with an equal vol of kaolin suspension. Repeat the test with a further aliquot of the plasma to which have been successively added 0-1 ml of phospholipid, calcium chloride solution, and the contact product. The clotting time with the product should not exceed 40 sec; if the time is shorter than that obtained with kaolin, the product may be diluted with tris until an equal time is obtained.
Finally, the product, adjusted as necessary as a result of the above tests, should be compared with kaolin activation of severely factor-VIII and factor-IX deficient plasmas. Approximately the same partial thromboplastin times should be obtained by kaolin activation and with the product on each plasma. Partially deficient factor-VIII and factor-IX plasma samples should then be assayed for factor VIII and factor IX respectively with the product and by the previous routine method (kaolin, or an earlier batch of 'contact product'), and similar results should be obtained.
Use of 'Contact Product' As mentioned above, the use of 'contact product' in factor-VIII and factor-IX assays has been modified from the technique described by Wilson et al (1971) by diluting the test samples in tris instead of in the substrate plasma, and by adding the contact product, instead of the calcium chloride, as the last reagent from whose addition the clotting is timed. This latter modification was found to reduce the experimental error, because it has been observed that when the 'contact product' was added before the calcium chloride, a delay in adding the calcium chloride led to a shortening of the clotting time.
The use of contact product in a screening test for defects of the 'contact factors' has been described in the paper by Ingram, Knights, Arocha-Piniango, Shepperd, and Perez-Requejo (1975) .
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